Search results
Coya Therapeutics Reports First Quarter 2024 Financial Results
GuruFocus.com via Yahoo Finance· 5 days agoThe expansion of COYA 302 to address Frontotemporal Dementia, Parkinsons Disease, and Alzheimers Disease underscores the company's strategic intent to leverage ...
Stifel Nicolaus Trims Denali Therapeutics (NASDAQ:DNLI) Target Price to $22.00
ETF DAILY NEWS· 5 days agoDenali Therapeutics (NASDAQ:DNLI – Free Report) had its target price decreased by Stifel Nicolaus from $26.00 to $22.00 in a research report sent to investors on Wednesday, Benzinga reports.
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 7 days agoCompany to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated